Search

Your search keyword '"Eisen, Howard J."' showing total 594 results
Start Over Author "Eisen, Howard J."
594 results on '"Eisen, Howard J."'

2. Novel Immunosuppression in Solid Organ Transplantation

Author

Konda, Prasad, Golamari, Reshma, Eisen, Howard J., Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Kuner, Rohini, Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Wang, KeWei, Editorial Board Member, and Eisen, Howard J., editor

Published
2022
Full Text
View/download PDF

3. Mechanistic Target of Rapamycin (mTOR) Inhibitors

Author

Wang, Denise, Eisen, Howard J., Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Kuner, Rohini, Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Wang, KeWei, Editorial Board Member, and Eisen, Howard J., editor

Published
2022
Full Text
View/download PDF

4. Discovery of non‐HLA antibodies associated with cardiac allograft rejection and development and validation of a non‐HLA antigen multiplex panel: From bench to bedside

Author

Butler, Carrie L, Hickey, Michelle J, Jiang, Ning, Zheng, Ying, Gjertson, David, Zhang, Qiuheng, Rao, Ping, Fishbein, Gregory A, Cadeiras, Martin, Deng, Mario C, Banchs, Hector L, Torre, Guillermo, DeNofrio, David, Eisen, Howard J, Kobashigawa, Jon, Starling, Randall C, Kfoury, Abdallah, Van Bakel, Adrian, Ewald, Gregory, Balazs, Ivan, Baas, Arnold S, Cruz, Daniel, Ardehali, Reza, Biniwale, Reshma, Kwon, Murray, Ardehali, Abbas, Nsair, Ali, Ray, Bryan, and Reed, Elaine F

Subjects
Transplantation, Prevention, Biotechnology, Heart Disease, Clinical Research, Organ Transplantation, Cardiovascular, Inflammatory and immune system, Allografts, Antibodies, Graft Rejection, HLA Antigens, Heart Transplantation, autoantibody, autoantigen, clinical research, practice, heart transplantation, cardiology, histocompatibility, immunogenetics, microarray, protein array, organ transplantation in general, rejection, translational research, science, clinical research/practice, heart transplantation/cardiology, microarray/protein array, translational research/science, Medical and Health Sciences, Surgery
Abstract

We analyzed humoral immune responses to nonhuman leukocyte antigen (HLA) after cardiac transplantation to identify antibodies associated with allograft rejection. Protein microarray identified 366 non-HLA antibodies (>1.5 fold, P 1R) with an area under the curve of 0.87 (P

Published
2020

11. Association of multiple metabolic and cardiovascular markers with the risk of cognitive decline and mortality in adults with Alzheimer’s disease and AD-related dementia or cognitive decline: a prospective cohort study

Author

Liu, Longjian, primary, Gracely, Edward J., additional, Zhao, Xiaopeng, additional, Gliebus, Gediminas P., additional, May, Nathalie S., additional, Volpe, Stella L., additional, Shi, Jingyi, additional, DiMaria-Ghalili, Rose Ann, additional, and Eisen, Howard J., additional

Published
2024
Full Text
View/download PDF

18. Association of multiple metabolic and cardiovascular markers with the risk of cognitive decline and mortality in adults with Alzheimer's disease and AD-related dementia or cognitive decline: a prospective cohort study.

Author

Longjian Liu, Gracely, Edward J., Xiaopeng Zhao, Gliebus, Gediminas P., May, Nathalie S., Volpe, Stella L., Jingyi Shi, DiMaria-Ghalili, Rose Ann, and Eisen, Howard J.

Subjects
COGNITION disorder risk factors, RISK assessment, GLUCOSE, HIGH density lipoproteins, HOMOCYSTEINE, CARDIOVASCULAR diseases, ALZHEIMER'S disease, RESEARCH funding, CREATININE, T-test (Statistics), LOGISTIC regression analysis, CARDIOVASCULAR diseases risk factors, FIBRIN fibrinogen degradation products, DESCRIPTIVE statistics, LONGITUDINAL method, WAIST circumference, BLOOD coagulation factors, DOSE-response relationship in biochemistry, ODDS ratio, COGNITION disorders, FIBRINOGEN, DEMENTIA, BLOOD pressure, TRIGLYCERIDES, ALBUMINS, DATA analysis software, CONFIDENCE intervals, BIOMARKERS, C-reactive protein, INTERLEUKINS, VASCULAR diseases, PROPORTIONAL hazards models, REGRESSION analysis, ADULTS
Abstract

Background and objectives: There is a scarcity of data stemming from largescale epidemiological longitudinal studies focusing on potentially preventable and controllable risk factors for Alzheimer's disease (AD) and AD-related dementia (ADRD). This study aimed to examine the effect of multiple metabolic factors and cardiovascular disorders on the risk of cognitive decline and AD/ADRD. Methods: We analyzed a cohort of 6,440 participants aged 45-84 years at baseline. Multiple metabolic and cardiovascular disorder factors included the five components of the metabolic syndrome [waist circumference, high blood pressure (HBP), elevated glucose and triglyceride (TG) concentrations, and reduced high-density lipoprotein cholesterol (HDL-C) concentrations], C-reactive protein (CRP), fibrinogen, interleukin-6 (IL-6), factor VIII, D-dimer, and homocysteine concentrations, carotid intimal-medial thickness (CIMT), and urine albumin-to-creatinine ratio (ACR). Cognitive decline was defined using the Cognitive Abilities Screening Instrument (CASI) score, and AD/ADRD cases were classified using clinical diagnoses. Results: Over an average follow-up period of 13 years, HBP and elevated glucose, CRP, homocysteine, IL-6, and ACR concentrations were significantly associated with the risk of mortality in the individuals with incident AD/ADRD or cognitive decline. Elevated D-dimer and homocysteine concentrations, as well as elevated ACR were significantly associated with incident AD/ADRD. Elevated homocysteine and ACR were significantly associated with cognitive decline. A dose-response association was observed, indicating that an increased number of exposures to multiple risk factors corresponded to a higher risk of mortality in individuals with cognitive decline or with AD/ADRD. Conclusion: Findings from our study reaffirm the significance of preventable and controllable factors, including HBP, hyperglycemia, elevated CRP, D-dimer, and homocysteine concentrations, as well as, ACR, as potential risk factors for cognitive decline and AD/ADRD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Long‐term post‐transplantation outcomes in patients with hypertrophic cardiomyopathy: Single‐center 35‐year experience.

Author

Mazur, Matylda, Bhat, Geetha, Popjes, Eric, Dowling, Robert, and Eisen, Howard J.

Subjects
HYPERTROPHIC cardiomyopathy, ARTIFICIAL blood circulation, HEART failure, DILATED cardiomyopathy, HEART transplantation, GRAFT rejection, CARDIOGENIC shock
Abstract

Background: Heart transplantation (HT) is the only option for most patients with end‐stage heart failure and hypertrophic cardiomyopathy (HCM) who fail medical therapy. Data on the long‐term outcomes post‐transplant in HCM individuals remain scarce. Methods: We analyzed data of 319 adult patients who underwent HT between 1984 and 2019. Patients were followed for cardiac allograft rejection, cardiac allograft vasculopathy (CAV), death, or re‐transplantation. Results: Outcomes of 24 patients with HCM, 160 with ischemic, and 135 with dilated cardiomyopathy were compared. During a mean follow‐up of 11.6 ± 7.2 (max 27.8), 16.7 ± 8.2 (max 32.7), and 16.1 ± 9.7 (max 34.6) years after HT in hypertrophic, ischemic, and dilated cardiomyopathy groups, respectively: 10‐year survival rate was 67%, 62%, 69%, respectively (p =.04). Post‐transplantation, HCM individuals more often than the other two studied groups required prolonged inotropic support (37%, 12%, 17%, respectively, p =.02), temporary mechanical circulatory support (45%, 13%, 14%, respectively, p <.01), and renal replacement therapy immediately post‐HT (55%, 19%, 24%, respectively, p <.01). No significant inter‐group differences were noted in the 10‐year freedom from acute allograft rejection (38%, 46%, 43%, respectively, p =.38) or 10‐year freedom from CAV (88%, 78%, 81%, respectively, p =.57). Conclusions: The long‐term post‐transplant prognosis of adult patients with hypertrophic cardiomyopathy is favorable despite more challenging immediate post‐HT course. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Vitamin D deficiency and metabolic syndrome: The joint effect on cardiovascular and all-cause mortality in the United States adults

Author

Liu, Longjian, Cui, Saishi, Volpe, Stella L., May, Nathalie S., Sukumar, Deeptha, DiMaria-Ghalili, Rose Ann, Eisen, Howard J., Liu, Longjian, Cui, Saishi, Volpe, Stella L., May, Nathalie S., Sukumar, Deeptha, DiMaria-Ghalili, Rose Ann, and Eisen, Howard J.

Abstract

BACKGROUND The long-term impact of vitamin D deficiency and metabolic syndrome (MetS) on cardiovascular disease (CVD) and all-cause mortality are still a matter of debate. AIM To test the hypotheses that lower serum 25 hydroxyvitamin D [25(OH)D] concentrations (a marker of vitamin D level) and MetS have a long-term impact on the risk of CVD and all-cause mortality, and individuals with vitamin D deficiency can be identified by multiple factors. METHODS A sample of 9094 adults, 20 to 90 years of age, who participated in the Third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1994) were followed through December 2015 was analyzed. The associations of serum 25(OH)D concentrations and MetS with CVD and all-cause mortality were analyzed longitudinally using Cox regression models. Classification and regression tree (CART) for machine learning was applied to classify individuals with vitamin D deficiency. RESULTS Of 9094 participants, 30% had serum 25(OH)D concentrations < 20 ng/mL (defined as vitamin D deficiency), 39% had serum 25(OH)D concentrations between 20 to 29 ng/mL (insufficiency), and 31% had serum 25(OH)D concentrations & GE;30 ng/mL (sufficiency). Prevalence of MetS was 28.4%. During a mean of 18 years follow-up, vitamin D deficiency and MetS were significantly associated with increased risk of CVD and all-cause mortality. Subjects with both vitamin D deficiency and MetS had the highest risk of CVD mortality (HR = 1.77, 95%CI: 1.22-2.58) and all-cause mortality (HR = 1.62, 95%CI: 1.26-2.09), followed by those with both vitamin D insufficiency and MetS for CVD mortality (HR = 1.59, 95%CI: 1.12-2.24), and all-cause mortality (HR = 1.41, 95%CI: 1.08-1.85). Meanwhile, vitamin D sufficiency significantly decreased the risk of CVD and all-cause mortality for those who even had MetS. Among the total study sample, CART analysis suggests that being non-Hispanic Black, having lower serum folate level, and being female were the first three predict

Published
2022

44. Vitamin d deficiency and metabolic syndrome: The joint effect on cardiovascular and all-cause mortality in the United States adults

Author

Liu, Longjian, Cui, Saishi, Volpe, Stella L., May, Nathalie S., Sukumar, Deeptha, DiMaria-Ghalili, Rose Ann, and Eisen, Howard J.

Subjects
Joint effect, Cox model and machine learning, Serum 25 hydroxyvitamin D concentration, Cardiovascular and all-cause mortality, Cardiology and Cardiovascular Medicine, Metabolic syndrome
Abstract

BACKGROUND The long-term impact of vitamin D deficiency and metabolic syndrome (MetS) on cardiovascular disease (CVD) and all-cause mortality are still a matter of debate. AIM To test the hypotheses that lower serum 25 hydroxyvitamin D [25(OH)D] concentrations (a marker of vitamin D level) and MetS have a long-term impact on the risk of CVD and all-cause mortality, and individuals with vitamin D deficiency can be identified by multiple factors. METHODS A sample of 9094 adults, 20 to 90 years of age, who participated in the Third National Health and Nutrition Examination Survey (NHANES III, 1988 to 1994) were followed through December 2015 was analyzed. The associations of serum 25(OH)D concentrations and MetS with CVD and all-cause mortality were analyzed longitudinally using Cox regression models. Classification and regression tree (CART) for machine learning was applied to classify individuals with vitamin D deficiency. RESULTS Of 9094 participants, 30% had serum 25(OH)D concentrations < 20 ng/mL (defined as vitamin D deficiency), 39% had serum 25(OH)D concentrations between 20 to 29 ng/mL (insufficiency), and 31% had serum 25(OH)D concentrations & GE;30 ng/mL (sufficiency). Prevalence of MetS was 28.4%. During a mean of 18 years follow-up, vitamin D deficiency and MetS were significantly associated with increased risk of CVD and all-cause mortality. Subjects with both vitamin D deficiency and MetS had the highest risk of CVD mortality (HR = 1.77, 95%CI: 1.22-2.58) and all-cause mortality (HR = 1.62, 95%CI: 1.26-2.09), followed by those with both vitamin D insufficiency and MetS for CVD mortality (HR = 1.59, 95%CI: 1.12-2.24), and all-cause mortality (HR = 1.41, 95%CI: 1.08-1.85). Meanwhile, vitamin D sufficiency significantly decreased the risk of CVD and all-cause mortality for those who even had MetS. Among the total study sample, CART analysis suggests that being non-Hispanic Black, having lower serum folate level, and being female were the first three predictors for those with serum 25(OH)D deficiency. CONCLUSION Vitamin D deficiency and MetS were significantly associated with increased risk of CVD and all-cause mortality. There was a significant joint effect of vitamin D deficiency and MetS on the risk of mortality. Findings of the CART analysis may be useful to identify individuals positioned to benefit from interventions to reduce the risk of CVD and all-cause mortality. Published version

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results